Plain-English translation of NCT06408298 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
Researchers are testing hydroxychloroquine, a medication commonly used to treat malaria and autoimmune diseases, to see if it affects prostate cancer cells in a specific way before surgery. About 20 men with early-stage prostate cancer will be randomly assigned to take either the medication or a placebo (inactive pill) for up to 28 days before their planned prostate removal surgery. The goal is to learn whether this medication changes how cancer cells work and whether it's safe to use in this setting.
Scientists want to understand how this medication might affect prostate cancer at the cellular level, which could potentially lead to new treatment strategies. This early-stage research will help doctors decide whether further testing of this treatment approach is worthwhile.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you join this study, you will take either the medication or a placebo pill twice daily for up to 28 days before your scheduled prostate removal surgery. You will not know which group you're in because the study is double-blinded. Researchers will monitor your safety during this period and collect samples of your prostate tissue during surgery to study how the medication affected your cancer cells. The study involves close follow-up with your medical team to watch for any side effects.
AI-generated summary from trial data ยท Jul 15, 2026 ยท Not medical advice
United States